A perspective on SARS-CoV-2 virus-like particles vaccines

Gao, Xiaoyang; Xia, Yeting; Liu, Xiaofang; Xu, Yinlan; Lu, Pengyang; dong, Zhipeng; Liu, Jing; Liang, Guozheng

doi:10.1016/j.intimp.2022.109650

Cited by 11 publications

(6 citation statements)

References 103 publications

(95 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the constant change of COVID-19 pandemic, more attention has focused on the comprehensive analysis of immune response induced by various viral proteins, including structural proteins [ 35 ]. Immunological studies analyzing the SARS-CoV-2 infectious process and vaccine immune response have not yet elucidated whether the specific T-cell responses against structural proteins, including the S protein, coordinate and/or enhance the humoral immunity targeting the S protein or whether that effect is a critical effective component of immune protection against SARS-CoV-2 infection [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

Study of the Effects of Several SARS-CoV-2 Structural Proteins on Antiviral Immunity

Yue

Zeng

et al. 2023

Vaccines

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike (S) protein is a critical viral antigenic protein that enables the production of neutralizing antibodies, while other structural proteins, including the membrane (M), nucleocapsid (N) and envelope (E) proteins, have unclear roles in antiviral immunity. In this study, S1, S2, M, N and E proteins were expressed in 16HBE cells to explore the characteristics of the resultant innate immune response. Furthermore, peripheral blood mononuclear cells (PBMCs) from mice immunized with two doses of inactivated SARS-CoV-2 vaccine or two doses of mRNA vaccine were isolated and stimulated by these five proteins to evaluate the corresponding specific T-cell immune response. In addition, the levels of humoral immunity induced by two-dose inactivated vaccine priming followed by mRNA vaccine boosting, two homologous inactivated vaccine doses and two homologous mRNA vaccine doses in immunized mice were compared. Our results suggested that viral structural proteins can activate the innate immune response and elicit a specific T-cell response in mice immunized with the inactivated vaccine. However, the existence of the specific T-cell response against M, N and E is seemingly insufficient to improve the level of humoral immunity.

show abstract

Section: Discussionmentioning

confidence: 99%

Study of the Effects of Several SARS-CoV-2 Structural Proteins on Antiviral Immunity

Yue

Zeng

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…VLPs is morphologically and immunologically similar to their natural counterparts; their formation without the involvement of viral genetic material avoids the risk of viral replication or proliferation and they are effective in stimulating humoral and cellular immunity. Therefore, they are widely used in novel vaccine design, such as SARS-CoV-2 VLPs vaccines and foot-and-mouth disease virus (FMDV) VLPs vaccines [ [57] , [58] , [59] , [60] ]. Current studies on PCV2-VLPs have worked on obtaining large amounts of Cap proteins through E. coli expression systems or insect baculovirus expression systems, self-assembling them into VLPs, and then purifying them to obtain higher-purity VLPs.…”

Section: Discussionmentioning

confidence: 99%

Both recombinant Bacillus subtilis Expressing PCV2d Cap protein and PCV2d-VLPs can stimulate strong protective immune responses in mice

Zhang,

Wu,

Peng

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…An example of a component viral vaccine is the protein subunit vaccine, which involves purifying specific components of the spike protein found on the surface of SARS-CoV-2. 161 Novavax and Covovax are typical examples of protein subunit vaccines. 162 Another type is the Virus-like Particle (VLP) vaccine.…”

Section: Current Drugs and Vaccine Statusmentioning

confidence: 99%

The Global Impact of COVID-19: Historical Development, Molecular Characterization, Drug Discovery and Future Directions

Dofuor,

Quartey,

Osabutey

et al. 2023

Clin Med�Insights�Pathol

View full text Add to dashboard Cite

In December 2019, an outbreak of a respiratory disease called the coronavirus disease 2019 (COVID-19) caused by a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in Wuhan, China. The SARS-CoV-2, an encapsulated positive-stranded RNA virus, spread worldwide with disastrous consequences for people’s health, economies, and quality of life. The disease has had far-reaching impacts on society, including economic disruption, school closures, and increased stress and anxiety. It has also highlighted disparities in healthcare access and outcomes, with marginalized communities disproportionately affected by the SARS-CoV-2. The symptoms of COVID-19 range from mild to severe. There is presently no effective cure. Nevertheless, significant progress has been made in developing COVID-19 vaccine for different therapeutic targets. For instance, scientists developed multifold vaccine candidates shortly after the COVID-19 outbreak after Pfizer and AstraZeneca discovered the initial COVID-19 vaccines. These vaccines reduce disease spread, severity, and mortality. The addition of rapid diagnostics to microscopy for COVID-19 diagnosis has proven crucial. Our review provides a thorough overview of the historical development of COVID-19 and molecular and biochemical characterization of the SARS-CoV-2. We highlight the potential contributions from insect and plant sources as anti-SARS-CoV-2 and present directions for future research.

show abstract

A perspective on SARS-CoV-2 virus-like particles vaccines

Cited by 11 publications

References 103 publications

Study of the Effects of Several SARS-CoV-2 Structural Proteins on Antiviral Immunity

Study of the Effects of Several SARS-CoV-2 Structural Proteins on Antiviral Immunity

Both recombinant Bacillus subtilis Expressing PCV2d Cap protein and PCV2d-VLPs can stimulate strong protective immune responses in mice

The Global Impact of COVID-19: Historical Development, Molecular Characterization, Drug Discovery and Future Directions

Contact Info

Product

Resources

About